José Garnacho-Montero1, Ana Díaz-Martín2, Luisa Cantón-Bulnes1, Paula Ramírez3, Rafael Sierra4, Dolores Arias-Verdú5, Marina Rodríguez-Delgado6, Ana Loza-Vázquez7, Jesús Rodriguez-Gomez6, Mónica Gordón3, Ángel Estella8, José Luis García-Garmendia9. 1. Unidad Clínica de Cuidados Intensivos, H. Universitario Virgen Macarena, Seville, Spain. 2. Unidad Clínica de Cuidados Intensivos, H. Universitario Virgen Rocío, Sevilla, Spain. 3. Servicio de Medicina Intensiva H, Universitario La Fe, Valencia, Spain. 4. Unidad Clínica de Cuidados Intensivos, H. Universitario Puerta del Mar, Cádiz, Spain. 5. Unidad Clínica de Cuidados Intensivos, H. Regional Universitario Carlos Haya, Málaga, Spain. 6. Unidad Clínica de Cuidados Intensivos, H. Reina Sofía, Córdoba, Spain. 7. Unidad Clínica de Cuidados Intensivos, H. Universitario Virgen de Valme, Seville, Spain. 8. Unidad Clínica de Cuidados Intensivos, H. de Jerez, Jerez, Cádiz, Spain. 9. Unidad de Cuidados Intensivos, Servicio de Cuidados Críticos y Urgencias, H. San Juan de Dios del Aljarafe, Bormujos, Seville, Spain.
Abstract
OBJECTIVE: The objective of this study was to evaluate the impact of the empirical therapy with fluconazole or an echinocandin on 30- and 90-day mortality in critically ill patients with candidemia. The outcome of patients in whom the empirical echinocandin was deescalated to fluconazole was also assessed. DESIGN: Retrospective, observational multicenter study. SETTING: Medical and surgical ICUs in nine Spanish hospitals. PATIENTS: Adult patients (≥ 18 yr) with an episode of Candida bloodstream infection during ICU admission from January 2011 to April 2016. INTERVENTIONS: Patient characteristics, infection-related variables, therapeutic interventions, and metastatic complications were reviewed. A propensity score-adjusted multivariable analysis was performed to identify the risk factors significantly associated with 30-day and 90-day mortality. MEASUREMENTS AND MAIN RESULTS: A total of 294 patients were diagnosed of candidemia in the participant ICUs. Sixty patients were excluded (other antifungals in the primary therapy or the patient died without empirical antifungal therapy). The study group comprised 115 patients who received fluconazole (30-day mortality, 37.4%) and 119 patients treated empirically with an echinocandin (30-day mortality, 31.9%). The use of an echinocandin in the empirical therapy was a protective factor for 30-day (odds ratio, 0.32; 95% CI, 0.16-0.66; p = 0.002) and 90-day mortality (odds ratio, 0.50; 95% CI, 0.27-0.93; p = 0.014) in the propensity score- adjusted multivariable analysis. Deescalation of the empirical echinocandin to fluconazole was not associated with a higher mortality or the occurrence of long-term complications. CONCLUSIONS: Empirical use of an echinocandin in critically ill patients with documented candidemia reduces mortality at 30 and 90 days significantly. Deescalation of the empirical echinocandin to fluconazole is safe and effective in fluconazole-susceptible infections.
OBJECTIVE: The objective of this study was to evaluate the impact of the empirical therapy with fluconazole or an echinocandin on 30- and 90-day mortality in critically illpatients with candidemia. The outcome of patients in whom the empirical echinocandin was deescalated to fluconazole was also assessed. DESIGN: Retrospective, observational multicenter study. SETTING: Medical and surgical ICUs in nine Spanish hospitals. PATIENTS: Adult patients (≥ 18 yr) with an episode of Candida bloodstream infection during ICU admission from January 2011 to April 2016. INTERVENTIONS:Patient characteristics, infection-related variables, therapeutic interventions, and metastatic complications were reviewed. A propensity score-adjusted multivariable analysis was performed to identify the risk factors significantly associated with 30-day and 90-day mortality. MEASUREMENTS AND MAIN RESULTS: A total of 294 patients were diagnosed of candidemia in the participant ICUs. Sixty patients were excluded (other antifungals in the primary therapy or the patient died without empirical antifungal therapy). The study group comprised 115 patients who received fluconazole (30-day mortality, 37.4%) and 119 patients treated empirically with an echinocandin (30-day mortality, 31.9%). The use of an echinocandin in the empirical therapy was a protective factor for 30-day (odds ratio, 0.32; 95% CI, 0.16-0.66; p = 0.002) and 90-day mortality (odds ratio, 0.50; 95% CI, 0.27-0.93; p = 0.014) in the propensity score- adjusted multivariable analysis. Deescalation of the empirical echinocandin to fluconazole was not associated with a higher mortality or the occurrence of long-term complications. CONCLUSIONS: Empirical use of an echinocandin in critically illpatients with documented candidemia reduces mortality at 30 and 90 days significantly. Deescalation of the empirical echinocandin to fluconazole is safe and effective in fluconazole-susceptible infections.
Authors: Ignacio Martin-Loeches; Massimo Antonelli; Manuel Cuenca-Estrella; George Dimopoulos; Sharon Einav; Jan J De Waele; Jose Garnacho-Montero; Souha S Kanj; Flavia R Machado; Philippe Montravers; Yasser Sakr; Maurizio Sanguinetti; Jean-Francois Timsit; Matteo Bassetti Journal: Intensive Care Med Date: 2019-03-25 Impact factor: 17.440
Authors: Alexis Tabah; Matteo Bassetti; Marin H Kollef; Jean-Ralph Zahar; José-Artur Paiva; Jean-Francois Timsit; Jason A Roberts; Jeroen Schouten; Helen Giamarellou; Jordi Rello; Jan De Waele; Andrew F Shorr; Marc Leone; Garyphallia Poulakou; Pieter Depuydt; Jose Garnacho-Montero Journal: Intensive Care Med Date: 2019-11-28 Impact factor: 17.440
Authors: E Moreno-García; P Puerta-Alcalde; G Gariup; M Fernández-Ruiz; L E López Cortés; G Cuervo; M Salavert; P Merino; M Machado; J Guinea; J García-Rodríguez; J Garnacho-Montero; C Cardozo; J Peman; M Montejo; J Fortún; B Almirante; C Castro; J Rodríguez-Baño; J M Aguado; J A Martínez; J Carratalà; A Soriano; C Garcia-Vidal Journal: Open Forum Infect Dis Date: 2021-05-16 Impact factor: 3.835
Authors: Seung A Byun; Eun Jeong Won; Mi-Na Kim; Wee Gyo Lee; Kyungwon Lee; Hye Soo Lee; Young Uh; Kelley R Healey; David S Perlin; Min Ji Choi; Soo Hyun Kim; Jong Hee Shin Journal: Front Microbiol Date: 2018-07-13 Impact factor: 5.640
Authors: Marco Falcone; Giusy Tiseo; Belen Gutiérrez-Gutiérrez; Giammarco Raponi; Paolo Carfagna; Chiara Rosin; Roberto Luzzati; Diego Delle Rose; Massimo Andreoni; Alessio Farcomeni; Mario Venditti; Jesus Rodríguez-Baño; Francesco Menichetti Journal: Open Forum Infect Dis Date: 2019-07-16 Impact factor: 3.835
Authors: Christian Ortega-Loubon; Beatriz Cano-Hernández; Rodrigo Poves-Alvarez; María Fe Muñoz-Moreno; Patricia Román-García; Sara Balbás-Alvarez; Olga de la Varga-Martínez; Esther Gómez-Sánchez; Estefanía Gómez-Pesquera; Mario Lorenzo-López; Eduardo Tamayo; María Heredia-Rodríguez Journal: J Clin Med Date: 2019-09-20 Impact factor: 4.241